NeuroOne Medical Technologies Corporation NMTC PHARMA

Q: What is the current share price of NeuroOne Medical Technologies Corporation (NMTC)?

As of 2026-09-19 21:16 PDT, NeuroOne Medical Technologies Corporation (NMTC) trades at $1.69 on NasdaqCM. Its 52-week range is $1.52 to $6.36.

Q: What is the market capitalisation of NMTC?

NeuroOne Medical Technologies Corporation (NMTC) has a market capitalisation of $15.39M on NasdaqCM.

Q: What is the P/E ratio of NMTC?

NMTC trades at a trailing price-to-earnings (P/E) ratio of -1.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.21.

Q: What is the return on equity (ROE) of NMTC?

NMTC has a return on equity (ROE) of -124.66%. Its return on capital employed (ROCE) is -49.83%.

Q: Is NMTC a good stock to buy?

This page provides a data-driven analysis of NeuroOne Medical Technologies Corporation (NMTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://nmtc1.com

Company Profile ↓

$1.69

-67.25% 1Y

Mkt Cap$15.39M

P/E-1.74

P/B3.21

52W High$6.36

52W Low$1.52

Book Value$0.43

EPS (TTM)$-0.97

Company Overview

NeuroOne Medical Technologies Corporation, a medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States. The company also provides solutions for spinal cord stimulation, brain stimulation, drug delivery and ablation solutions for patients suffering from epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other pain-related neurological disorders. The company has a collaboration with the Department of Neurology's Division of Epilepsy at the University of Minnesota Medical School to advance a study evaluating epilepsy therapies. The company is based in Eden Prairie, Minnesota.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 145.0% CAGR over the past five years.

Recent Developments

Sep 2025 Revenue of $9.10M (+163.5% YoY); net profit $-3.61M.
Trailing 12 Months Year-on-year growth — revenue +16.3%.
5-Year Trend Long-term compounding — revenue CAGR 145.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	145.01%
1 Year:	16.30%

Stock Price Performance

1 Year:	-67.25%
6 Months:	-64.30%
3 Months:	-51.16%
1 Month:	+3.68%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 4% of range

$1.52 $6.36

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)41.08 · Neutral

Price Performance

1M+3.68%

3M-51.16%

6M-64.30%

1Y-67.25%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 145.0% over 5 years.

CONS

Trading 73.4% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-1.74

Industry PE

24.83

Forward P/E

-6.04

PEG Ratio

Book Value

$0.43

Price to Book

3.21

P/S

1.02

EV/EBITDA

-1.41

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

145.01%

Profit 5Y

Revenue (YoY)

16.30%

Earnings (YoY)

Profitability & Returns

ROCE

-49.83%

ROE

-124.66%

ROA

-58.07%

Profit Margin

-59.71%

Op Margin

Gross Margin

23.00%

EPS (Latest Qtr)

$-0.28

EPS (TTM)

$-0.97

Balance Sheet & Liquidity

Debt/Equity

4.65

Quick Ratio

1.54

Current Ratio

2.84

Debt

$175.34K

Total Assets

$7.86M

Current Assets

$7.40M

Working Capital

$7.92M

Ownership

Promoter Holding

25.60%

Chg in Prom Hold

0.37%

FII / Inst Holding

22.45%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$15.39M

Total Revenue (TTM)

$12.47M

EBITDA

$-7.66M

Free Cash Flow

$-4.57M

Operating Cash Flow

$-7.05M

Shares Outstanding

9.11M

Gross Margin

23.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	NMTC NeuroOne Medical Technologies Corporation PHARMA	1.69	-1.74	$15.39M	0.00%	-49.83%	-124.66%	145.01%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Dec 2018	Mar 2019	Jun 2019	Dec 2019	Mar 2020	Jun 2020	Dec 2020	Mar 2021	Jun 2021	Dec 2021	Mar 2022	Jun 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	71.47K	18.24K	40.10K	33.75K	36.58K	32.05K	114.58K	466.18K	629.91K	977.65K	1.38M	825.78K	-	1.39M	1.70M	2.74M	2.89M	1.86M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	615.49K	781.22K	1.21M	1.32M	871.79K
Gross Profit	252	165	303	139	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-37.66K	-21.12K	-21.84K	-13.10K	-36.22K	-6.41K	-12.31K	31.50K	243.67K	266.31K	390.42K	281.87K	-	771.06K	914.84K	1.53M	1.57M	990.26K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.45M	2.80M	2.90M	3.28M	3.39M
Operating Income	-4.73K	-3.90K	-16.02K	-6.12K	-1.83K	-18.67K	-2.59K	-4.39K	-14.11K	-8.60K	-516.06K	-888.69K	-893.79K	-773.78K	-1.10M	-1.17M	-1.08M	-1.52M	-1.86M	-1.81M	-1.38M	-1.59M	-2.14M	-2.40M	-3.03M	-2.81M	-3.06M	-2.76M	-1.78M	-3.50M	-3.51M	-3.39M	-2.89M	-2.79M	-	-2.68M	-1.89M	-1.37M	-1.71M	-2.40M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.20M	-1.42M	-1.55M	-1.37M	-2.32M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	9.32K	0	0	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.27M	-1.50M	-1.62M	-1.44M	-2.38M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Income	-5.13K	-4.23K	-16.02K	-6.12K	-11.58K	-22.14K	-10.07K	-8.96K	-24.70K	-12.23K	-729.58K	-1.29M	-944.39K	-1.63M	-1.36M	-1.26M	-1.35M	-2.21M	-1.86M	-4.64M	-1.35M	-7.09M	-1.96M	-2.39M	-2.95M	-2.81M	-3.06M	-2.76M	-1.73M	-3.52M	-3.47M	-3.34M	-2.86M	-2.77M	-	-2.27M	-1.50M	-1.62M	-1.44M	-2.38M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.25	-0.18	-0.19	-0.17	-0.11	-0.21	-0.20	-0.14	-0.11	-0.10	0.36	-0.42	-0.18	-	-0.18	-0.28
R&D Expense	-	-	-	-	-	-	-	-	-	-	72.04K	156.72K	-	234.93K	105.05K	225.53K	209.17K	436.31K	422.78K	501.82K	342.10K	447.15K	934.16K	1.08M	901.13K	1.06M	1.21M	1.23M	1.56M	1.71M	1.89M	1.48M	1.27M	1.19M	1.17M	1.51M	1.18M	-	1.39M	1.47M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Revenue	1.17K	5.40K	921	1.25K	773	0	0	-	-	-	171.17K	1.95M	3.45M	9.10M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	241.96K	1.50M	2.37M	3.96M
Gross Profit	1.17K	3.26K	921	-	-	-	-	-	-	-	-70.79K	456.52K	1.08M	5.14M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	9.96M	12.41M	12.97M	9.37M
Operating Income	-	-	-	-25.09K	-35.91K	-30.91K	-32.61K	-5.81M	-4.90M	-	-10.03M	-11.96M	-11.89M	-4.23M
EBITDA	-	-	-	-	-	-	-	-	-	-	-9.91M	-11.66M	-11.84M	-3.01M
Interest Expense	-	-	-	-	-	-	-	-	-	-	0	0	228.99K	334.06K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-10.00M	-11.86M	-12.32M	-3.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net Income	-6.04K	-27.60K	-27.60K	-30.55K	-36.24K	-62.86K	-47.77K	-6.78M	-13.64M	-	-10.00M	-11.86M	-12.32M	-3.61M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-3.78	-3.90	-2.76	-0.54
R&D Expense	-	-	-	-	-	-	-	1.53M	2.08M	3.93M	4.93M	6.94M	5.07M	4.98M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Assets	-	9.13K	13.85K	1.12K	525	205	1.84K	756.93K	249.99K	218.72K	532.62K	4.76M	-	12.82M	8.10M	5.37M	10.79M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	12.18M	7.31M	4.63M	10.23M
Cash & Equivalents	-	-	-	-	-	-	-	-	26.47K	13.26K	260.75K	4.04M	-	8.16M	5.32M	1.46M	6.57M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	704.54K	1.73M	2.64M	2.23M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	33.24K	0	176.64K	1.26M
Total Liabilities	-	13.45K	17.13K	18.36K	30.82K	35.59K	83.33K	1.02M	5.29M	4.61M	1.77M	2.69M	-	3.22M	1.85M	4.55M	3.71M
Current Liabilities	-	2.95K	4.63K	18.36K	30.82K	35.59K	83.33K	677.19K	3.91M	3.80M	1.77M	2.36M	-	3.10M	1.79M	2.21M	2.30M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	202.90K	184.40K	260.16K	266.81K
Total Equity	1.22K	-4.32K	-3.28K	-17.24K	-30.29K	-35.39K	-81.49K	-266.22K	-5.04M	-4.40M	-1.24M	2.07M	-	9.60M	6.25M	822.01K	7.07M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	2.70M	3.99M	5.14M	8.33M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2010	Dec 2011	Dec 2012	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Operating Cash Flow	-5.09K	-27.43K	-13.73K	-5.40M	-3.43M	-	-7.52M	-12.89M	-11.01M	-2.84M
Investing Cash Flow	-	0	0	-123.35K	-122.43K	-	-3.24M	2.65M	-120.20K	-81.74K
Financing Cash Flow	13.00K	32.15K	1.00K	5.77M	7.32M	-	12.02M	7.40M	7.27M	8.03M
Capital Expenditure	-	-	-	-58.35K	-122.43K	-	-275.23K	-384.12K	-120.20K	-81.74K
Free Cash Flow	-	-	-	-5.45M	-3.55M	-	-7.79M	-13.27M	-11.13M	-2.92M
Net Change in Cash	-	-	-	-	-	-	1.26M	-2.84M	-3.86M	5.11M

Ratios (Annual)

Figures in %.

Metric	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Gross Margin %	100.0%	60.4%	100.0%	-	-	-	-	-	-	-	-41.4%	23.4%	31.3%	56.5%
Operating Margin %	-	-	-	-2,009.0%	-4,646.1%	-	-	-	-	-	-5,860.2%	-612.3%	-344.3%	-46.5%
Net Margin %	-517.9%	-511.4%	-2,997.2%	-2,446.3%	-4,688.7%	-	-	-	-	-	-5,842.0%	-607.4%	-356.7%	-39.6%
ROE %	139.8%	842.4%	160.1%	100.9%	102.4%	77.1%	17.9%	547.9%	-660.2%	-	-104.1%	-189.8%	-1,498.5%	-51.0%
ROCE %	-	-	-	82.8%	101.5%	37.9%	-40.9%	469.7%	-203.9%	-	-103.2%	-189.6%	-376.6%	-49.8%

Shareholding Pattern

Insiders

25.60%

Institutions

22.45%

Public Float

30.17%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Bleichroeder LP	7.32%	666.67K	$926.66K
2	Vanguard Capital Management LLC	3.87%	352.77K	$490.36K
3	Bard Associates Inc.	3.35%	305.43K	$424.54K
4	Perkins Capital Management, Inc.	2.69%	244.66K	$340.07K
5	Geode Capital Management, LLC	1.03%	93.56K	$130.04K
6	Sio Capital Management, LLC	0.91%	82.77K	$115.05K
7	Renaissance Technologies, LLC	0.78%	70.86K	$98.50K
8	Vanguard Fiduciary Trust Co	0.54%	49.02K	$68.14K
9	Essex Investment Management Co LLC	0.48%	43.58K	$60.57K
10	Cambridge Investment Research Advisors Inc.	0.31%	28.50K	$39.61K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for NMTC

Google News ue, 08 Sep 2026

Insider Purchase: Chief Business Officer of $NMTC Buys 33,333 Shares - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxNSlhOQ2hIOEt2MXZ1VnZOWnlWVnBxSkVtMzVFbW5LZXFDRFgtRHBKR29Xc3hCUHEyNVRIYkJjTEhjT2tDc1p2dFo5dm9qQ1BURV9WTEZaX1FvaUtKdXRGWVNSLVJNN1d2dU1lOVg2YXc1NFVjRUhpLURsSmdORjZ6ZUZ4SG0wREJJX09rQX…

Google News ue, 08 Sep 2026

Insider Stock Purchases: September 08, 2026 - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMihwFBVV95cUxOZHA0ajYwMDNxRjRNeGUyWFlDcVg1M3k3aWk3OFo0RHhzX2dIRDFWdzhBd3AyamlKeTFfVkMwTEJIUXhPUlR2Y3ZLU3BTU0pDN3FDdEdCY0t3V3BiVEdoT0N1bkJiRmg2VkxHTmRRM2dFSkFrR1h6QkhFendxSzJGLWZSVC1aV1k?oc=5" …

Google News ue, 08 Sep 2026

NeuroOne CBO David Wambeke buys $66,999 in company stock By Investing.com - Investing.com India

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOY1psdFE0Q1l3YzJ6RkpKMW9RRkc2WFJVWjZUbUlZWWJWU3Q5aXEtMXpvTlBydU9CN0dCMVJMMjN5UDcyWEVVV1puZGZmX2ZnMTV0YWdTVTBzTGZES0hncW1TS0VzX1pBYjlwUU5IcUVkT3VxdWFGeGp6bnNVZDZ2UEU3YTZ6ck1uNFNodW…

Google News Fri, 28 Aug 2026

NeuroOne (NMTC) grants officer options at $1.77 - Stock Titan

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxOZGFxaU5Wdm1mdXdsX0hmSzM2TzFXbG9BZHc5SmZ5QmJFYTRNQU1PZTktZ0VJelYwdnZ3eW42MU1FZVh2Q1VaWEZvSnpqZU5PYXczcHJ4aW5CY3BOSTVwU0pIVG5oSzVOcVRYeVpyM19OS0dmdWVYN29rQTItLW5WdU5uRjM0TDFraUFjcU…

Google News hu, 25 Jun 2026

NMTC Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE82MkFmNkhXVkJ3NTJrSGVzNUZMRHVVR0ZBTDRKWUU1WlhjTlJydGEtTlQxanoyMFhUMjR5UnlyaldrLW9mdWExSldxWVFKMkQwdlJXRzlRYnRpY2pfWXhuT0Y4Mk1MZ1QtWGhaVU56eWE0eFZCN2Vrd05n?oc=5" target="_blank">NMT…

Google News ue, 14 Apr 2026

NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq Compliance - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPVHhPY3NEcEFMWjZWYzFhYkpLcVVwenk3cUZFbGVqN2VoX3VXSHlmVUJJZHJ3a3pLcGVrWUlaZnNkLVI1MjdfTGZ3dTVwc01JNGpnX1h1MTJWYVc3OXZZcXhWU2VtUWxlbzBGa2k0Y1JiS1hrZGkySzY3dmp6X216bHNiSmtUa0dMbkVsUn…

NMTC — Frequently Asked Questions

What is the current share price of NeuroOne Medical Technologies Corporation (NMTC)?

As of 2026-09-19 21:16 PDT, NeuroOne Medical Technologies Corporation (NMTC) trades at $1.69 on NasdaqCM. Its 52-week range is $1.52 to $6.36.

What is the market capitalisation of NMTC?

NeuroOne Medical Technologies Corporation (NMTC) has a market capitalisation of $15.39M on NasdaqCM.

What is the P/E ratio of NMTC?

NMTC trades at a trailing price-to-earnings (P/E) ratio of -1.74. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.21.

What is the return on equity (ROE) of NMTC?

NMTC has a return on equity (ROE) of -124.66%. Its return on capital employed (ROCE) is -49.83%.

Is NMTC a good stock to buy?

This page provides a data-driven analysis of NeuroOne Medical Technologies Corporation (NMTC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

NeuroOne Medical Technologies Corporation NMTC PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Insider Purchase: Chief Business Officer of $NMTC Buys 33,333 Shares - Quiver Quantitative

Insider Stock Purchases: September 08, 2026 - Quiver Quantitative

NeuroOne CBO David Wambeke buys $66,999 in company stock By Investing.com - Investing.com India

NeuroOne (NMTC) grants officer options at $1.77 - Stock Titan

NMTC Forecast — Price Target — Prediction for 2027 - tradingview.com

NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq Compliance - finance.yahoo.com

NMTC — Frequently Asked Questions

What is the current share price of NeuroOne Medical Technologies Corporation (NMTC)?

What is the market capitalisation of NMTC?

What is the P/E ratio of NMTC?

What is the return on equity (ROE) of NMTC?

Is NMTC a good stock to buy?

Explore More